Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

The Effect of Therapy With Bevacizumab in Chronic Central Serous Chorioretinopathy

This study is enrolling participants by invitation only.
Information provided by:
Hallym University Medical Center Identifier:
First received: March 18, 2009
Last updated: NA
Last verified: March 2009
History: No changes posted

The pathophysiology of central serous chorioretinopathy remains controversial. traditional treatment is laser photocoagulation or photodynamic therapy.Recently Bevacizumab (Avastin, Genetech),an antibody to vascular endothelial growth factor (VEGF),has known antipermeability properties and therefore may theoretically reverse the changes seen in central serous chorioretinopathy. The aim of this study is To investigate concentrations of growth factors and inflammatory cytokines and to report the effect of therapy with bevacizumab in eyes with central serous chorioretinopathy

Condition Intervention
Central Serous Chorioretinopathy
Procedure: intravitreal injection with anterior paracentesis

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Pharmacokinetics Study
Intervention Model: Parallel Assignment
Masking: Single Blind (Investigator)
Primary Purpose: Treatment
Official Title: Intraocular Concentrations of Growth Factors and Cytokines in Chronic Central Serous Chorioretinopathy And the Effect of Therapy With Bevacizumab

Resource links provided by NLM:

Further study details as provided by Hallym University Medical Center:

Primary Outcome Measures:
  • Concentrations of growth factors and inflammatory cytokines in Aqueous humor [ Time Frame: at baseline ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • Central macular thickness at optical coherence tomography [ Time Frame: baseline, 1 month, 3 months, 6 months ] [ Designated as safety issue: Yes ]

Estimated Enrollment: 10
Study Start Date: March 2009
Estimated Study Completion Date: March 2010
Estimated Primary Completion Date: March 2010 (Final data collection date for primary outcome measure)
Intervention Details:
    Procedure: intravitreal injection with anterior paracentesis
    0.1cc Aqueous humor samples were taken each time an intravitreal injection of bevacizumab (2.5 mg in 0.1 ml)
    Other Names:
    • Bevacizumab (Avastin, Genetech)
    • an antibody to vascular endothelial growth factor (VEGF)

Ages Eligible for Study:   30 Years to 60 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients with a diagnosis of central serous chorioretinopathy
  • Idiopathic neurosensory retinal elevation demonstrated by optical coherent tomography
  • Presence of focal leaks at the level of the RPE on fluorescein angiography

Exclusion Criteria:

  • Known side effects of systemic bevacizumab administration
  • Have a significant cardiovascular or thromboembolic history or were pregnant
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

No Contacts or Locations Provided
  More Information

No publications provided

Responsible Party: Hallym University Medical Center Identifier: NCT00864773     History of Changes
Other Study ID Numbers: 2009-3-16
Study First Received: March 18, 2009
Last Updated: March 18, 2009
Health Authority: Korea: Food and Drug Administration

Additional relevant MeSH terms:
Central Serous Chorioretinopathy
Eye Diseases
Retinal Diseases
Endothelial Growth Factors
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Antineoplastic Agents
Growth Inhibitors
Growth Substances
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses processed this record on November 25, 2014